Login to Your Account



In The Clinic NEWS
LONDON – Tigenix NV is claiming the crown as first to deliver positive phase III data in an allogeneic stem cell therapy, reporting statistically significant results for Cx601 in the treatment of complex perianal fistulas caused by Crohn's disease.
Macrocure Ltd. shares (NASDAQ:MCUR) hit an all-time low on Thursday after a futility analysis of partial data from a pivotal phase III study revealed that the company's sole candidate, the cell therapy Curexcell, is unlikely to meet its primary endpoint of helping heal venous leg ulcers faster than a placebo.

A head-to-head study pitting an implantable exenatide-filled osmotic pump developed by Intarcia Therapeutics Inc. against the blockbuster Januvia over a year of type 2 diabetes treatment proved the pump superior in reducing HbA1c levels and producing weight loss.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: